Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study

AIDS Patient Care and STDs

Volumn 26, Issue 5, 2012, Pages 259-264

  McDonald, Cheryl ^a   Uy, Jonathan ^b   Hu, Wenhua ^b   Wirtz, Victoria ^b   Juethner, Salome ^b   Butcher, David ^b   McGrath, Donnie ^b   Farajallah, Awny ^b   Moyle, Graeme ^c  

^a Tarrant County Infectious Disease Associates   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; LOPINAVIR PLUS RITONAVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT RESPONSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; FEMALE; HIV-1; HUMANS; HYPERBILIRUBINEMIA; LOPINAVIR; MALE; MEDICATION ADHERENCE; OLIGOPEPTIDES; PYRIDINES; QUALITY OF LIFE; QUESTIONNAIRES; RITONAVIR;

EID: 84860493969     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0092     Document Type: Article

References (40)

1. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718 (Pubitemid 43884298)
2. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47:161-167 (Pubitemid 351172182)
3. Bentue-Ferrer D, Arvieux C, Tribut O, Ruffault A, Bellissant E. Clinical pharmacology, efficacy and safety of atazanavir: A review. Expert Opin Drug Metab Toxicol 2009;5:1455-1468
4. Satija P, Parikh F, Aggarwal V, Sharma B, Hakim A, Pai- Dhungat JV. Indirect hyperbilirubinemia with indinavir. J Assoc Physicians India 2002;50:1316-1317
5. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171-1175
6. Keshavan P, Deem TL, Schwemberger SJ, Babcock GF, Cook-Mills JM, Zucker SD. Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J Immunol 2005;174:3709-3718 (Pubitemid 40354082)
7. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008;121:781-788
8. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A doseranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18-29 (Pubitemid 36091481)
9. Squires K, Lazzarin A, Gatell JM, et al. Comparison of oncedaily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011-1019 (Pubitemid 38989366)
10. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19: 685-694 (Pubitemid 40593073)
11. Korenblat KM, Berk PD. Hyperbilirubinemia in the setting of antiviral therapy. Clin Gastroenterol Hepatol 2005;3: 303-310 (Pubitemid 40488336)
12. Efficacy and safety of atazanavir-based therapy in antiretroviral- naive HIV-1-infected subjects, both with and without ritonavir: 96-week results from AI424-089. 4th International AIDS Conference on HIV Pathogenesis and Treatment. Sydney, Australia: July 22-25
13. Molina JM,Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-655
14. Molina JM, Andrade-Villaneuva J, Echevarria J, et al. Oncedaily atazanavir/ritonavir compared with twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV- 1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53: 323-332
15. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6:481-493 (Pubitemid 27431704)
16. Chesney MA, Ickovics JR, Chambers DB, et al. Selfreported adherence to antiretroviral medications among participants in HIV clinical trials: The CTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000;12:255-266 (Pubitemid 30426745)
17. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001;26:82-92 (Pubitemid 32115053)
18. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718 (Pubitemid 43884298)
19. Lankisch TO, Behrens G, Ehmer U, et al. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy-An extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol 2009;50:1010-1018
20. Park WB, Choe PG, Song KH, et al Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1.z*28 allele frequency. Clin Infect Dis 2010;51:101-106
21. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development Sydney, Australia: Of antiretroviral therapy- associated hyperbilirubinemia. J Infect Dis 2005;192: 1381-1386 (Pubitemid 41401151)
22. Strassburg CP, Lankisch TO, Manns MP, Ehmer U. Family 1uridine-5'-diphosphate glucuronosyltransferases (UGT1A): From Gilbert's syndrome to genetic organization and variability. Arch Toxicol 2008;82:415-433
23. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010;85:190-200
24. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497 (Pubitemid 32173638)
25. Holmberg SD, Moorman AC, Greenberg AE. Trends in rates of myocardial infarction among patients with HIV. N Engl J Med 2004;350:730-732 (Pubitemid 38364634)
26. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: A population-based cohort study. Clin Infect Dis 2007;44: 1625-1631 (Pubitemid 46871511)
27. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol Heart Circ Physiol 2000;278:H643-H651 (Pubitemid 30131266)
28. Erdogan D, Gullu H, Yildirim E, et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intimamedia thickness in both men and women. Atherosclerosis 2006;184:431-437 (Pubitemid 43049731)
29. Kawamura K, Ishikawa K, Wada Y, et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol 2005;25: 155-160 (Pubitemid 40054269)
30. Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010;56:1535-1543
31. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1.*28 allele, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008;198:1-11
32. Vitek L, Jirsa M, Brodanova M, et al. Gilbert syndrome and ischemic heart disease: A protective effect of elevated bilirubin levels. Atherosclerosis 2002;160:449-456 (Pubitemid 34159340)
33. Yoshino S, Hamasai S, Ishida S, et al. Effect of serum concentration of bilirubin in the obese patients: The action for coronary endothelial function and inflammatory stress. J Am Coll Cardiol 2010;55:E1434
34. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21:41-46 (Pubitemid 44912535)
35. Rodriguez JM, Hermida JM, Casado JL, et al. The use of atazanavir in HIV-infected patients with liver cirrhosis: Lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score. AIDS 2011;25:1006-1009
36. Rodriguez NS, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C- > T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006;42:291-295 (Pubitemid 43054206)
37. Malan DR, Krantz E, David N, et al. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic Ill) 2010;9:34-42
38. Malan N, Su J, Mancini M, et al. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: Data from the CASTLE study. AIDS Care 2010;22: 677-686
39. Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006;44:1324-1332 (Pubitemid 44748383)
40. Merchante N, Lopez-Cortes LF, Delgado-Fernandez M, et al. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/hepatitis C virus-coinfected patients. AIDS Patient Care STDs 2011;25:395-402